Nothing said here yet.
to join the conversation.
Certara has seen its share price move around in recent years, which puts fresh attention on a simple question for anyone looking at the stock today.
Around 20 financial institutions were affected by cyberattacks earlier this month, with hackers allegedly exploiting stolen partner-bank credentials and vulnerabilities in payment APIs to siphon off funds.
Price targets for Certara are clustering in the mid to high single digits, with recent moves centering around the US$9 to US$10 range.
AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases.Dublin, Sept.
AI, machine learning and big data are advancing virtual screening and precision medicine, creating opportunities in molecular modeling, docking and data integration.Dublin, Sept.
Biosimulation adoption is rising in drug development, driven by AI, personalized medicine, regulatory support and R&D cost savings, with strong opportunities in services and Asia-Pacific.Dublin, Sept.
On August 4, Certara (NASDAQ:CERT) reported second-quarter 2026 results that told two different stories at once.
In early August 2026, Certara reported second-quarter results showing slightly higher sales of US$93.27 million but a much larger net loss of US$55.27 million, alongside executive reshuffling including the departure of President and Chief Commercial Officer Leif Pedersen and the appointment of Julien Perrier as Chief Commercial Officer and Eric Jahn as Chief Information Officer.
Software revenue hit 53% of total as AI-assisted code boosted development 65% year over year.
Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?